Ph 2 data show EO2463-induced CD8 T-cell expansion correlates with PFS in patients with indolent NHL in the watch-and-wait setting
“The correlation between the robust CD8 T cell expansion induced by EO2463 and PFS is a landmark finding that creates an imperative for further study and offers new hope for patients suffering from iNHL. It suggests that EO2463, which has been well-tolerated to date, may effectively extend PFS as a standalone therapy without hurting quality of life in this generally older and fragile patient population. We want to prioritize patients classified for watch-and-wait, an observational protocol, because they currently receive no active treatment, despite having to live with the grave psychological impact of their cancer diagnosis,” said Pierre Belichard, Chief Executive Officer of Enterome. “Based on these and other data, we believe EO2463 is ready to start the final stage of registrational clinical development as a first-in-class therapeutic for patients with iNHL in a watch-and-wait setting. We are in active discussions with potential investors and partners to find the best way to bring this product to patients.”
Share:
More News
“With this financing, we are well positioned to complete IND-enabling studies and advance TAVST01 toward its planned IND submission, bringing us closer to delivering a scalable, readily available, and potentially transformative cell therapy for patients with solid tumors”, said Dr. Ivan Horak, Founder and Chief Executive Officer of Tikva Allocell.
“We continue to be very encouraged by the longer-term data from our Phase 2 J201 study, and today’s announcement marks a pivotal step forward in our mission to bring safusidenib as a comprehensive treatment option for patients with all types of IDH1-mutant glioma,” said David Hung, M.D., Founder, President, and
We are proud to have pioneered these oncology assets and look forward to advancing them through Kaveri Therapeutics,” said Vinita Gupta, Chief Executive Officer, Lupin. “The strength of these assets, combined with Kaveri’s seasoned leadership team, positions us to accelerate the development of targeted oncology therapies with the goal of
Dr Jonathan Kwok, Co-Founder, President and Chief Medical Officer, Infinitopes, said, “Entering the clinic is a defining milestone for successful future medicines. For Infinitopes, VISTA represents the first clinical evaluation of our integrated approach that combines Precision Immunomics target discovery with proven viral vectors, to engineer precise, off-the-shelf therapies for